Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of ruxolitinib (INC424) in myelofibrosis
2010-024473-39Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Primary endpoint: Safety. Started May 2011; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2010-024473-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024473-39.